Home›Stock Screener›Sequent Scientific

Sequent Scientific Share Price Today | Stock Price & Sequent Scientific Share Screener

SEQUENT Pharmaceuticals
Live Share Price NSE
₹193.98
▼ -5.45 (-2.73%)
2026-01-21 00:00:00
Live Share Price BSE
₹194.10
▼ -5.30 (-2.66%)
2026-01-21 00:00:00

As of January 21, 2026, the live Sequent Scientific share price (NSE: SEQUENT) is ₹193.98 on NSE and ₹194.10 on BSE, down 2.73% from the previous close, with shares trading between ₹192.62 and ₹199.89 in today's trading session, and a 52-week range of ₹190.05–₹252.00. Check SEQUENT price range for the annual price range and momentum. Use the Sequent Scientific stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Sequent Scientific opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.

Key Statistics and Valuation Ratios

Over the trailing twelve months the company reported revenue of ₹403 and net income of ₹10, with EBITDA of ₹48, an operating margin of 11.0% and a profit margin of 2.5%.

Sequent Scientific Market Cap ₹5,067.77 Cr.
SEQUENT P/E Ratio (TTM) 165.81
Sequent Scientific P/B Ratio 10.60
EPS (TTM) ₹0.88
Dividend Yield -
Debt to Equity 0.71
SEQUENT 52 Week High ₹252.00
Sequent Scientific 52 Week Low ₹190.05
Operating Margin 11.00%
Profit Margin 2.48%
SEQUENT Revenue (TTM) ₹403.00
EBITDA ₹48.00
Net Income ₹10.00
Total Assets ₹1,602.00
Total Equity ₹770.00

Sequent Scientific Share Price Chart

Track the current stock price of Sequent Scientific with an interactive chart. Analyse SEQUENT share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Sequent Scientific stock quote in one place.

The quote of ₹193.98 sits between the 52-week low of ₹190.05 and the 52-week high of ₹252.00, and the latest session moved -2.73% from the previous close.

Sequent Scientific Company Profile - Fundamental Screener

Screen Sequent Scientific company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for SEQUENT shares across the equity market and its stock price history, plus the wider market trend.

The company is classified under the Healthcare sector and the Pharmaceuticals industry, and it trades under ISIN INE807F01027.

Company Details

Classification

Sector Healthcare
Industry Pharmaceuticals
Sub-Sector Pharmaceuticals
Segment E

Identifiers and Leadership

ISIN INE807F01027

Sequent Scientific Balance Sheet Screener

Screen SEQUENT balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.

For 2025, total assets were ₹1,602 against total liabilities of ₹1,602, up from ₹1,540 in 2024.

Latest statistics put total assets at ₹1,602 and shareholder funds at ₹770, with a leverage ratio of 0.71.

Item 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016

Assets

Total Assets 1,602 1,540 1,529 1,451 1,393 1,463 1,388 1,343 1,905 1,528
Current Assets 873 811 780 783 714 704 600 538 728 491
Fixed Assets 586 592 605 564 536 577 498 476 684 587

Liabilities

Total Liabilities 1,602 1,540 1,529 1,451 1,393 1,463 1,388 1,343 1,905 1,528
Current Liabilities 327 200 221 199 156 236 207 227 247 290
Non-Current Liabilities 0 0 0 0 0 0 0 0 0 0

Shareholders' Equity

Total Equity 770 713 749 740 776 732 747 685 994 948
Share Capital 50 50 50 50 50 50 49 49 49 48
Reserves & Surplus 654 607 649 633 678 637 657 599 928 885

Sequent Scientific Income Statement Screener - Profit & Revenue Analysis

Screen Sequent Scientific income statement and profit fundamentals. Analyze SEQUENT quarterly results. Sequent Scientific reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.

For 2025-Mar, revenue was ₹403 and net profit was ₹10, equal to earnings per unit of ₹0.37, at an operating margin of 11%.

In that period expenses were ₹356, interest cost ₹15 and tax ₹6. The next period listed, 2025-Jun, shows revenue of ₹445 and net profit of ₹18.

Item 2025-Mar 2025-Jun 2025-Sept 2024-Mar 2024-Jun 2024-Sept 2024-Dec 2023-Mar 2023-Jun 2023-Sept 2023-Dec 2022-Mar 2022-Jun 2022-Sept 2022-Dec

Revenue and Expenses

Revenue 403 445 426 365 393 373 397 368 334 356 337 388 342 339 378
Expenses 356 391 370 334 348 334 357 432 365 331 307 350 342 335 365

Operating Costs and Margins

EBITDA 48 55 56 32 45 39 40 -63 -31 25 30 37 0 4 13
Operating Profit % 11.00% 12.00% 13.00% 8.00% 11.00% 9.00% 9.00% -18.00% -10.00% 4.00% 7.00% 9.00% 0.00% 1.00% 3.00%
Depreciation 16 15 16 17 16 17 17 15 14 15 16 13 14 13 14
Interest 15 14 14 12 16 14 15 11 11 13 13 6 7 8 10

Profit and Earnings

Profit Before Tax 16 26 27 3 12 8 8 -89 -56 -3 2 18 -21 -18 -10
Tax 6 8 8 1 3 2 2 4 -21 4 -9 8 -6 -13 0
Net Profit 10 18 20 1 9 6 7 -92 -35 -7 11 10 -15 -4 -10
EPS 0.37 0.57 0.59 -0.04 0.26 0.11 0.14 -3.77 -1.40 -0.34 0.33 0.36 -0.60 -0.15 -0.36

Sequent Scientific Cash Flow Screener - Liquidity Fundamentals

Screen SEQUENT cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.

In 2025-March, operating activities generated ₹83, and net cash flow was an outflow of ₹2.

Over the same period, investing activities used ₹25 and financing activities used ₹61.

Item 2025-March 2024-March 2023-March 2022-March 2021-March 2020-March 2019-March 2018-March 2017-March 2016-March

Cash from Operations and Investing

Operating Activities 83 31 17 31 115 115 116 45 -7 0
Investing Activities -25 -6 -65 -94 10 -72 -68 7 -116 -311

Financing and Net Cash

Financing Activities -61 -1 32 67 -139 -43 -20 -57 147 309
Net Cash Flow -2 23 -16 4 -14 0 28 -5 24 -2

Sequent Scientific Shareholding Pattern Screener

See Sequent Scientific shareholding pattern with promoter, FII, and DII holdings. Check Sequent Scientific promoter holding and ownership changes for SEQUENT on TickJournal, and see how institutional stock price moves affect the market.

In 2025-Mar, promoters held 52.61%, foreign institutions 6.05%, domestic institutions 12.82% and the public 23.43%, spread across 158,152 shareholders.

The shareholder count was 158,152 in 2025-Mar, compared with 147,320 in 2025-Jun.

Item 2025-Mar 2025-Jun 2025-Sept 2025-Dec 2024-Mar 2024-Jun 2024-Sept 2024-Dec

Promoter Holding

Promoter Holding 52.61% 52.61% 52.33% 61.43% 52.79% 52.78% 52.76% 52.61%

Institutional Investors

FII Holding 6.05% 6.15% 5.91% 3.16% 6.16% 5.70% 6.45% 6.10%
DII Holding 12.82% 12.98% 12.91% 7.35% 7.59% 8.06% 9.99% 12.02%

Government, Public and Others

Govt Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Public Holding 23.43% 22.37% 22.72% 19.24% 24.43% 25.01% 24.00% 23.82%
Other Holding 5.09% 5.89% 6.13% 8.83% 9.02% 8.45% 6.80% 5.46%
Shareholder Count 158,152 147,320 144,085 135,389 166,593 163,693 154,603 162,574

Dividend Yield Screener - Share Price & Share Analysis

Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Sequent Scientific. Sequent Scientific dividend yield can be compared with peers and other stocks in the market.

The latest dividend recorded was ₹0.00 per unit for 2026-March, a yield of 0.00%, compared with ₹0.00 for 2025-March.

Dividends are listed for 10 periods, with the three most recent payouts at ₹0.00, ₹0.00 and ₹0.00 per unit.

Period Dividend Per Share Dividend Yield
2026-March ₹0.00 0.00%
2025-March ₹0.00 0.00%
2024-March ₹0.00 0.00%
2023-March ₹0.00 0.00%
2022-March ₹0.00 0.00%
2021-March ₹0.50 0.37%
2020-March ₹0.00 0.00%
2019-March ₹0.20 0.26%
2018-March ₹0.20 0.28%
2017-March ₹0.00 0.00%

Sequent Scientific Stock Index Membership - Nifty & Sensex

See which indices include Sequent Scientific stock. Check SEQUENT index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.

The company is listed in 5 indices, including BSE 1000.

Among the benchmarks tracked are BSE 1000, BSE INDEX BSE HC, BSE INDEX SMLCAP, NIFTY MICROCAP250.

Complete Index List

BSE 1000
BSE INDEX BSE HC
BSE INDEX SMLCAP
NIFTY MICROCAP250
NIFTY TOTAL MKT

Sequent Scientific Market Events Screener - Corporate Actions

Get Sequent Scientific corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Sequent Scientific stock events that may affect SEQUENT share price, along with derivatives, futures and options activity and sector gainers.

11 corporate actions are listed, the most recent entry being Dividend dated .

It is followed by Annual General Meeting dated and Merger - Demerger dated December 8, 2025.

Announcement Date Record Date Event Type Information Price Impact
Dividend ₹ 0.50 /share -26.73%
Annual General Meeting NA 7.61%
2025-12-08 2025-12-08 Merger - Demerger 100:56 0.00%
2025-11-14 2025-11-14 Quarterly Result Announcement NA 6.35%
2025-08-30 2025-08-30 Extraordinary General Meeting NA -2.53%
2025-08-26 2025-08-26 Extraordinary General Meeting NA -0.29%
2025-08-08 2025-08-08 Quarterly Result Announcement NA -0.48%
2025-08-08 2025-08-08 Annual General Meeting NA -3.66%
2025-05-20 2025-05-20 Quarterly Result Announcement NA 15.69%
2025-02-11 2025-02-11 Quarterly Result Announcement NA -2.09%
2024-11-13 2024-11-13 Quarterly Result Announcement NA -3.87%

Sequent Scientific Competitors Screener - Peer Stocks Comparison

Screen SEQUENT competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.

The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.

Company Market Cap P/E Ratio Revenue YoY Growth Net Profit RSI
Sun Pharmaceutical 387,205 38.30 54,729 9.71% 10,980 26.52
Divis Laboratories 159,626 65.60 9,712 18.67% 2,191 29.62
Torrent Pharmaceuticals 134,593 64.70 11,539 6.99% 1,911 56.71
Cipla 111,343 20.68 28,410 7.12% 5,291 23.28
Lupin 99,048 22.89 22,910 13.74% 3,306 57.69
Dr Reddys Laboratories 97,376 16.97 33,741 16.73% 5,725 23.20
Zydus Life Science 87,884 17.63 23,511 18.55% 4,615 34.17
Mankind Pharma 87,692 49.29 12,744 20.90% 2,007 40.97
Alkem Laboratories 68,397 28.48 13,458 3.70% 2,216 52.47
Aurobindo Pharma 66,310 19.82 32,346 9.43% 3,484 35.55

Sequent Scientific Company Announcements - News & Reports Screener

Screen SEQUENT latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.

20 recent announcements are listed, the latest dated January 21, 2026.

The next most recent announcements are dated January 9, 2026 and January 9, 2026.

Date Update Actions
2026-01-21 Announcement under Regulation 30 (LODR)-Credit Rating -
2026-01-09 Intimation Of Change Of Name Of The Company. -
2026-01-09 Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 -
2025-12-30 Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS -
2025-12-29 Shareholder Meeting / Postal Ballot-Scrutinizer"s Report -
2025-12-23 Announcement under Regulation 30 (LODR)-Change in Management -
2025-12-19 Closure of Trading Window -
2025-12-17 Disclosures under Reg. 10(6) of SEBI (SAST) Regulations 2011 -
2025-12-17 Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 -
2025-12-17 Disclosures under Reg. 29(1) of SEBI (SAST) Regulations 2011 -
2025-12-16 Announcement under Regulation 30 (LODR)-Scheme of Arrangement -
2025-12-16 Announcement under Regulation 30 (LODR)-Change in Management -
2025-12-16 Board Meeting Outcome for Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2025 (SEBI Listing Regulations) And Outcome Of Board Meeting Of The Company -
2025-12-11 Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS -
2025-11-29 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2025-11-28 Shareholder Meeting / Postal Ballot-Notice of Postal Ballot -
2025-11-28 Announcement under Regulation 30 (LODR)-Scheme of Arrangement -
2025-11-27 Announcement under Regulation 30 (LODR)-Amendments to Memorandum & Articles of Association -
2025-11-26 Intimation Of Record Date Under Regulation 42 Of SEBI -
2025-11-22 Announcement under Regulation 30 (LODR)-Scheme of Arrangement -

Frequently Asked Questions

How is the company valued right now?

The current quote is ₹193.98, within a 52-week range of ₹190.05 to ₹252.00. The P/E ratio is 165.81 and the P/B ratio is 10.60, with earnings per unit of ₹0.88. Market capitalisation stands at ₹5,067.77 Cr. The company operates in the Healthcare sector, in the Pharmaceuticals industry, so compare these ratios with its sector peers in the table above.

About This Data

Quotes are sourced from the NSE and the BSE. Key statistics were last updated on January 23, 2026. This page covers 10 balance sheet periods, 15 income statement periods, 10 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.